Gene FOXJ1 Linked to Chemotherapy Resistance in Advanced Prostate Cancer

A newly identified gene, FOXJ1, may play a critical role in driving resistance to taxane chemotherapy in men with advanced prostate cancer, according to research led by investigators at Weill Cornell Medicine and Beth Israel Deaconess Medical Center. The findings, published in Nature Communications on February 14, 2026, offer potential fresh strategies for predicting treatment response and developing more effective therapies.

Understanding Taxane Resistance

Taxanes, such as docetaxel, are a cornerstone of treatment for metastatic castration-resistant prostate cancer (mCRPC). However, many patients initially respond to these drugs but eventually develop resistance, leading to disease progression. Understanding the mechanisms behind this resistance is crucial for improving patient outcomes. Given that taxanes remain the only chemotherapy agents with demonstrated survival benefit in advanced prostate cancer, understanding how and why resistance develops is an urgent need for patients.

The Role of FOXJ1

Researchers created mouse models of prostate cancer that developed resistance to docetaxel after repeated treatment cycles, mirroring the clinical scenario in humans. Analysis of these resistant tumors revealed significantly higher expression levels of FOXJ1 and related genes compared to tumors that remained sensitive to the drug.

While FOXJ1 is known for its role in the formation of cilia – hair-like structures on cells – the study uncovered a surprising function in regulating microtubules within prostate cancer cells. Microtubules are essential for cell division and survival, acting as both structural support and transport pathways. Taxane drugs work by binding to microtubules, stabilizing them and disrupting their normal function, ultimately preventing cancer cell division.

How FOXJ1 Confers Resistance

The research demonstrated that increasing FOXJ1 levels in prostate cancer cells reduced their sensitivity to docetaxel, both in laboratory experiments and in mouse models. Conversely, reducing FOXJ1 expression made cancer cells more vulnerable to the drug. FOXJ1 alters the behavior of microtubules, preventing docetaxel from binding and stabilizing them effectively. The team also identified other genes regulated by FOXJ1 that influence microtubule function, suggesting a broader network promoting chemotherapy resistance.

Clinical Relevance

Analysis of tumor samples from clinical studies showed that FOXJ1 gene amplification was more common in patients who had received taxane treatment. Data from the CHAARTED clinical trial indicated that patients with higher baseline FOXJ1 levels experienced poorer outcomes when docetaxel was added to standard hormone therapy. ^{1 2}

“It was clear that the patients who overexpressed FOXJ1 did not benefit as much from taxane therapy,” said Dr. Paraskevi Giannakakou, professor of pharmacology in medicine and director of laboratory research in the Division of Hematology and Medical Oncology at Weill Cornell Medicine. ³

Future Directions

These findings suggest that measuring FOXJ1 gene activity in tumors could help doctors predict which patients are likely to develop drug resistance and tailor treatment strategies accordingly. The research also opens the door to developing new therapies that specifically target the FOXJ1 pathway, potentially restoring the effectiveness of taxane chemotherapy. ⁴

“This is a previously unrecognized role for the FOXJ1 transcription factor, and it could serve as a potential biomarker to help us identify patients who are more likely to benefit from these types of treatments,” added Dr. Giannakakou.

Key Takeaways

• FOXJ1 gene expression is elevated in taxane-resistant prostate cancer.
• FOXJ1 regulates microtubule dynamics, interfering with the mechanism of action of taxane drugs.
• High FOXJ1 levels are associated with poorer outcomes in patients treated with docetaxel.
• FOXJ1 may serve as a biomarker to predict treatment response and guide therapeutic decisions.

Further research is needed to validate these findings and translate them into clinical practice, but this discovery represents a significant step forward in understanding and overcoming chemotherapy resistance in prostate cancer.